Pyxis Oncology reports positive updated MICVO Phase 1 monotherapy data
Pyxis Oncology said its MICVO Phase 1 monotherapy study showed 36% cORR and 94% DCR, with rapid and deep responses and activity across HPV status and prior-treatment subgroups.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pyxis Oncology reports positive updated Phase 1 MICVO monotherapy data
Pyxis Oncology says updated Phase 1 monotherapy study data for micvotabart pelidotin (MICVO) is positive in 2L+ recurrent/metastatic head and neck squamous cell carcinoma.